News | April 05, 2022
IDMA’s two-day Diamond Jubilee celebrations in Mumbai on April 14-15
The two-day event will showcase achievements and address issues pertaining to the industry
The two-day event will showcase achievements and address issues pertaining to the industry
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Subscribe To Our Newsletter & Stay Updated
